Professional Documents
Culture Documents
Risk Factors:
• Many sexual partners. The greater your number of sexual partners — and the greater your
partner's number of sexual partners — the greater your chance of acquiring HPV.
• Early sexual activity (younger than 20). Having sex at an early age increases your risk of
HPV.
• Other sexually transmitted infections (STIs). Having other STIs — such as chlamydia,
gonorrhea, syphilis and HIV/AIDS — increases your risk of HPV.
• A weakened immune system. You may be more likelyto develop cervical cancer if your
immune system is weakened by another health condition and you have HPV.
• Smoking. Smoking is associated with squamous cell cervical cancer.
Pathophysiology
• Cervical cancer begins when healthy cells in the cervix develop changes
(mutations) in their DNA. A cell's DNA contains the instructions that tell a cell
what to do.
• Healthy cells grow and multiply at a set rate, eventually dying at a set time. The
mutations tell the cells to grow and multiply out of control, and they don't die. The
accumulating abnormal cells form a mass (tumor). Cancer cells invade nearby
tissues and can break off from a tumor to spread (metastasize) elsewhere in the
body.
• It isn't clear what causes cervical cancer, but it's certain that HPV plays a role. HPV
is very common, and most people with the virus never develop cancer. This means
other factors — such as your environment or your lifestyle choices — also
determine whether you'll develop cervical cancer.
Assessment Findings:
Subjective Cues Objective cues
• Fatigue • Weight loss due to the caloric needs of the tumor, taking away from the
• Loss of appetite needs of the body.
• Generalized weakness • • Anorexia.
Discomfort in the pelvis • Vagina bleeding after intercourse, between periods or after menopause •
area Watery, bloody vaginal discharge that may be heavy and have a foul odor •
Pelvic pain or pain during intercourse
Special Notation
• Surgical removal of the cervix (trachelectomy)
• hysterectomy
• Radiation therapy.
Laboratory/Diagnostic Findings:
• Pelvic exam
• Pap smear (all women aged between 21 and 65 should get an annual pap smear)
• HPV DNA test. The HPV DNA test involves testing cells collected from the cervix for
infection with any of the types of HPV that are most likely to lead to cervical cancer.
• Biopsy is confirmative for cancer.
• Endo-cervical curettage
• Cone biopsy
Medications • epirubincin
• vincristine
• methotrexate • Docetaxel
• fluorouracil
• doxorubicin
• Administer analgesics for pain control:
Hormonal therapy: • morphine, fentanyl
UTERINE CANCER
What is Uterine Cancer?
• Cancer of the uterine
endometrium
(fundus or corpus) has
increased in incidence,
partly because people
are living longer and because reporting is more accurate. Most uterine cancers are
endometrioid (that is, originating in the lining of the uterus).
• After breast, colorectal, and lung cancer, endometrial cancer is the fourth most common
cancer in women and the most common pelvic neoplasm. Cumulative exposure to
estrogen is considered the major risk factor.
• This exposure occurs with the use of estrogen replacement therapy without the use of
progestin, early menarche, late menopause, never having children, and anovulation.
Other risk factors include infertility, diabetes, hypertension, gallbladder disease, and
obesity.
• Tamoxifen may also cause proliferation of the uterine lining, and women receiving this
medication for treatment or prevention of breast cancer are monitored by their
oncologists.
• Postmenopausal bleeding
• Obesity that results in increased estrone levels (related to excess weight) resulting
from conversion of androstenedione to estrone in body fat, which exposes the
uterus to unopposed estrogen
• Unopposed estrogen therapy (estrogen used without progesterone, which offsets
the risk of unopposed estrogen)
• Other: nulliparity, truncal obesity, late menopause (after 52 years of age) and,
possibly, use of tamoxifen
Assessment Findings
• Endometrial aspiration or biopsy
• Ultrasonography
Medical Management
• Treatment of endometrial cancer consists of total hysterectomy (discussed later in this chapter) and
bilateral salpingo-oophorectomy and node sampling. Depending on the stage, the therapeutic
approach is individualized and is based on stage, type, differentiation, degree of invasion, and node
involvement.
• Whole pelvis radiotherapy is used if there is any spread beyond the uterus. Preoperative and
postoperative treatments for stage II and beyond may include pelvic, abdominal, and vaginal
intracavitary radiation.
• Recurrent cancer usually occurs inside the vaginal vault or in the upper vagina, and metastasis usually
occurs in lymph nodes or the ovary. Recurrent lesions in the vagina are treated with surgery and
radiation. Recurrent lesions beyond the vagina are treated with hormonal therapy or chemotherapy.
Progestin therapy is used frequently. Patients should be prepared for such side effects as nausea,
depression, rash, or mild fluid retention with this therapy.